Grant ID RP160440
Awarded On November 19, 2015
Title Targeting the undruggable: a first-in-class inhibitor of the HIF-2 transcription factor
Program Academic Research
Award Mechanism Individual Investigator
Institution/Organization The University of Texas Southwestern Medical Center
Principal Investigator/Program Director James Brugarolas
Cancer Sites Kidney and Renal Pelvis
Contracted Amount $899,412
Lay Summary

Kidney cancer is particularly prevalent in Texas. One third of patients present with metastasis and another third will develop metastases. In the metastatic setting, kidney cancer is incurable. Recent discoveries about the biology of kidney cancer have led to 7 new drugs. These drugs extend life expectancy, but do not cure. The drugs target two classes of kidney cancer drivers, growth factors and kinases. However, suitable drug targets have been exhausted and there are no good strategies to target proteins in other classes. The most important driver of kidney cancer, the HIF-2 complex, belongs to a class of proteins, transcription factors, that have traditionally been considered “undruggable...

Read More